Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study-Reference-Cited by-同舟云学术

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

Published:2023-10 Issue: Volume:192 Page:113245
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Gelderblom Hans,Jones Robin L.,Blay Jean-Yves^ORCID,George Suzanne^ORCID,von Mehren Margaret^ORCID,Zalcberg John R.,Kang Yoon-Koo,Razak Albiruni Abdul,Trent Jonathan,Attia Steven,Le Cesne Axel,Siontis Brittany L.,Goldstein David,Boye Kjetil^ORCID,Sanchez Cesar,Steeghs Neeltje,Rutkowski Piotr,Druta Mihaela,Serrano César,Somaiah Neeta^ORCID,Chi Ping^ORCID,Harrow Brooke^ORCID,Becker Claus,Reichmann William,Sherman Matthew L.,Ruiz-Soto Rodrigo^ORCID,Heinrich Michael C.,Bauer Sebastian^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. Gastrointestinal stromal tumour;Rubin;The Lancet,2007

2. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies;Soreide;Cancer Epidemiol,2016

3. Gastrointestinal stromal tumours (GISTs): novel therapeutic strategies with immunotherapy and small molecules;Vallilas;Int J Mol Sci,2021

4. The management of metastatic GIST: current standard and investigational therapeutics;Kelly;J Hematol Oncol,2021

5. PDGFRA activating mutations in gastrointestinal stromal tumours;Heinrich;Science,2003

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape;Journal of Clinical Oncology;2024-04-20

2. Adverse Event Reporting in Cancer Clinical Trials: Incorporating Patient-Reported Methods. A Systematic Scoping Review;The Patient - Patient-Centered Outcomes Research;2024-04-08

3. Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers;Receptors;2024-03-04

4. Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study;Cancers;2024-02-28

5. Ripretinib for the treatment of advanced, imatinib‐resistant gastrointestinal stromal tumors;Journal of Digestive Diseases;2023-10-19